Cerliponase Alfa

DRUG2 trials

Sponsors

BioMarin Pharmaceutical, David L Rogers, MD

Conditions

Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2Neuronal Ceroid Lipofuscinosis Type 2

Phase 1

Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2

Active, not recruitingNCT05152914

David L Rogers, MDNeuronal Ceroid Lipofuscinosis Type 2

Start: 2021-11-01End: 2027-03-06Target: 5Updated: 2026-04-30

Unknown Phase

Cerliponase Alfa Observational Study in the US

Active, not recruitingNCT04476862

BioMarin PharmaceuticalLate-Infantile Neuronal Ceroid Lipofuscinosis Type 2

Start: 2020-08-19End: 2030-08-31Target: 35Updated: 2026-06-30

Related Papers

Enzyme Replacement Therapy in CLN2-Associated Retinopathy.

2025-03-241 citations